The theme of this year’s ASCO meeting is “advancing quality through innovation.” As always, the vast scope of this annual meeting is daunting. In order to give our readers an ongoing analysis of ASCO ’10, The Oncology Forum will be posting daily from Chicago, parsing out the best sessions and most relevant clinical information.
The theme of this year’s annual ASCO meeting is “advancing quality through innovation.” As always, the vast scope of this international meeting is daunting. In order to give our readers an ongoing analysis of ASCO ’10, The Oncology Forum will be posting daily from Chicago, parsing out the best sessions and most relevant clinical information.
The Forum will also highlight the most important practice management information, nuts & bolts tips that will help your practice’s bottom line and analysis of how Obama’s healthcare bill will impact the ability to treat your patients in the brave new world of comparative effectiveness research (CER) and steep Medicare cuts.
Here’s a new feature from this year’s meeting:
Trials in Progress Poster Session
The new Trials in Progress Poster Session will facilitate awareness of and dialogue about open, ongoing clinical trials. It differs from other Poster Sessions in that:
--outcomes data or results are not included,
--the goal is to promote discussion among trial investigators, to encourage recruitment of new investigators or sites, and to stimulate discussion of successor or confirmatory trials,
--the focus is on the background of the science behind the trial, and preclinical or earlier-phase data (preferably with references) is encouraged.
Also, watch The Forum for exclusive interviews from the meeting's top presenters.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.